Pharmacology VIII

a. preventing release of acetylcholine

b. preventing synthesis of acetylcholine

c. enhancing destruction of acetylcholine

d. competeing with acetylcholine for receptor sites

e. producing physiologic effects opposite to those of acetylcholine

a. depressing acetylcholinesterase release

b. inhibiting acetylcholinesterase activity

c. increasing the rate of acetylcholine synthesis

d. acting like acetylcholine at ganglionic sites

e. increasing the amount of acetylcholine released from nerve terminals

a. adenylate cyclase

b. monoamine oxidase

c. phosphodiesterase

d. acetylcholinesterase

e. carbonic anhydrase

1. (a), (b), and (c)

2. (a), (c), and (d)

3. (a), (d) and (e)

4. (b), (d), and (e)

5. (c), (d) and (e)

a. atropine

b. phenytoin

c. pralidoxime

d. propantheline

e. phenobarbital

a. curarine

b. edrophonium

c. mecamylamine

d. succinylcholine

e. gallamine triethodide

a. atropine

b. muscarine

c. neostigmine

d. pilocarpine

e. acetylcholine

a. blocked

b. enhanced and prolonged

c. less intense and of shorter duration

d. none of the above. The action of acetylcholine is not affected by neostigmine

a. is a congener of acetylcholine

b. is a competitive blocking agent

c. has no effect on acetylcholinesterase

d. is more potent than diisopropylfluorophosphate

e. is capable of acting directly on the end-plate

a. atropine

b. epinephrine

c. diazepam (Valium)

d. neostigmine (Prostigmine)

e. succinylcholine (Anectine)

a. atropine

b. ephedrine

c. neostigmine

d. scopolamine

e. mecamylamine

a. diazepam

b. promethazine

c. physostigmine

d. propantheline

e. diphenhydramine

a. adrenergic

b. cholinergic

c. ganglionic blocking

d. adrenergic blocking

e. cholinergic blocking

1. (a) and (b) only

2. (a), (b), and (c)

3. (b) and (c) only

4. (b), (c), and (d)

5. (d) and (e)

1. (a) and (b) only

2. (a), (b), and (c)

3. (b) and (c) only

4. (b), (c), and (d)

5. (d) and (e)

a. release of adrenal catecholamines

b. blockade of vagus nerve activity

c. blockade of the nicotinic cholinergic receptor

d. stimulation of the alpha adrenergic receptor

e. stimulation of the beta adrenergic receptor

a. mydriasis

b. bradycardia

c. increased peristalsis

d. stimulation of sweat glands

e. increased secretion by bronchial glands

a. CNS stimulation

b. CNS depression

c. decreased salivation

d. muscle fasiculation

e. extrapyramidal reactions

1. (a), (b), (d) and (e)

2. (a), (b), and (e) only

3. (a),and (c)

4. (b) and (e) only

5. All of the above

a. skeletal muscle fasiculation

b. excessive salivation

c. bronchoconstriction

d. hot, dry skin

e. diarrhea

a. diarrhea

b. salivation

c. convulsions

d. bonchiolar constriction

e. skeletal muscle paralysis

1. (a) and (c)

2. (b) and (d)

3. (b), (d), and (e)

4. (d) and (e)

5. All of the above

a. CNS excitation and tachycardia

b. intestinal cramps and diarrhea

d. ptyalism and increased sweating

e. constriction of the pupils and blurring of vision

a. atropine

b. levodopa

c. acetylcholine

d. physostigmine

a. shock

b. convulsion

c. cardiac arrhythmia

d. respiratory paralysis

e. dehydration from vomiting and diarrhea

a. bradycardia

b. lacrimation

c. vasoconstriction

d. extreme salivation

e. weakness of voluntary muscles

a. it is subject to rapid metabolism in the liver

b. it rapidly redistributes away from the NMJ

c. it is subject to inactivation by plasma esterases

d. it undergoes rapid inactivation in the GI tract

a. anti-adrenergic

b. cholinomimetic

c. sympatholytic

d. anti-cholinergic

e. sympathomimetic